BioChain Engineering Research System
for Key Technologies in the Prevention and Control of Chronic Diseases
Engineering R&D drives high-tech innovations, constructing a comprehensive solution for the “Triple E*” approach to chronic diseases.
Based on innovative liquid biopsy technology, BioChain has established a strategic research framework with the aim of developing proprietary methodologies for the early detection, diagnosis, and intervention (hereinafter referred to as “Triple E*”) of chronic diseases such as cancer, cardiovascular disease, and cerebrovascular disease. Our research center comprises seven medical engineering research laboratories, including Epigenetics, Multi-omics Integration, Transcription, Proteomics, Bioinformatics, Automation, and Material Engineering laboratories. These laboratories provide guidance and assistance in applying and transforming clinical outcomes.
Sample Processing Technology
BioChain has developed the industry's first automated equipment for nucleic acid extraction and purification. It includes cell lysis, nucleic acid extraction and purification, and bisulfite conversion on a single automated platform. It can significantly reduces the testing time by 60% when compared to manual operation.
Liquid Biopsy Technology
BioChain offers a wide range of proprietary cfDNA extraction and laboratory preparation kits. Our cfDNA extraction kit can be used with various sample types, such as blood, plasma, and urine. It also delivers 20% higher extraction purity and efficiency compared to high-quality products in the market. Our laboratory preparation kit also uses a single-stranded cfDNA laboratory preparation method for methylation sequencing. Its optimal sequencing depth is 77% higher than other industry-leading products when the same amount of cfDNA is used.
Biomarker Discovery Technology
BioChain primarily integrates Whole Genome Bisulfite Sequencing (WGMS) and Next Generation Sequencing (NGS) methylation-specific panels to ensure sufficient sequencing coverage of cancer-related genes and to distinguish genome-wide methylation levels. A high-efficiency biomarker discovery procedure is achieved when it is combined with self-developed AI interpretation and standardized validation systems.
Pan-Cancer Early Detection
Our current service for the six high-risk cancers in China (lung, colorectal, gastric, esophageal, liver, and thyroid cancers) requires only 10 mL of peripheral blood and has an overall sensitivity, specificity, and tumor tissue-of-origin agreement rate of up to 91.0%, 95.3%, and 85.9%, respectively.(Data as of July 2023)
Artificial Intelligence (AI) Interpretation Technology
BioChain has built a high-performance computing (HPC) cluster with a computing capacity of over 200 trillion operations per second. Combined with its algorithm system, it can seamlessly execute quality control, sequence alignment, feature extraction, and other processes of high-throughput sequencing data, and build multi-dimensional comprehensive models. At present, BioChain has obtained more than ten exclusive algorithm patents related with the Multidimensional and Omics Data Integration Algorithm (MODE).
BioChain has established an advanced industrialization platform and adheres strictly to the ISO13485 Quality Management System. With this approach, the company effectively executes all process stages, including project approval, product development, performance validation, production transfer, preclinical research, registration testing, clinical trials, registration declaration, and marketing authorization. In addition, BioChain operates an industrialization base covering almost 40,000 square meters in the Beijing Economic-Technological Development Area (BDA), enabling it to provide testing products and services to millions of individuals annually.
As a leader in the “Triple E*” approach to tackling chronic diseases, BioChain started with a strong focus on gastrointestinal (GI) cancers and has now gradually expanded into dozens of other cancers, as well as other major diseases such as cardiovascular and cerebrovascular diseases.